文献速递腹部CT

影像组学诊断结直肠癌肝转移组织病理学生长模式预测贝伐珠单抗化疗疗效

Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy.
PubMed 文献 · Eur J Radiol · 2021-07-13

多中心回顾性研究纳入119例不可切除结直肠癌肝转移患者,基于增强MDCT构建影像组学模型诊断组织病理学生长模式(促纤维增生型D或替代型R)。模型预测早期反应的AUC在病灶层面为0.707、患者层面为0.720;D型患者1年PFS显著长于R型或混合型(P<0.001),RAD_HGP是1年PFS唯一独立预测因素。

要点

  • 影像组学可无创诊断CRLM的HGP分型(D型 vs R型)。
  • RAD_HGP预测早期反应AUC病灶层面0.707、患者层面0.720。
  • D型患者1年PFS显著优于R型或混合型,RAD_HGP为独立预测因素。

核心结论

  • 基于ceMDCT的影像组学模型诊断的HGP可有效预测接受含贝伐珠单抗化疗的CRLM患者的1年PFS。

研究设计与样本

  • 多中心回顾性研究,纳入119例不可切除CRLM患者,基于增强多排CT(ceMDCT)构建影像组学模型诊断HGP(D型或R型)。
  • 以形态学反应标准评估病灶层面和患者层面的早期反应,采用逻辑回归和ROC曲线分析。
  • 1年PFS采用Kaplan-Meier曲线计算,Cox比例风险回归分析获取风险比。

关键影像表现/征象

  • 共识别206个D型模式和140个R型模式病灶。
  • 多病灶患者中52例为D型、31例为R型、36例为混合型(D+R)。

诊断标准与关键数值

  • RAD_HGP预测早期反应的AUC:病灶层面0.707,患者层面0.720。
  • D型患者1年PFS显著长于R型或混合型患者(P<0.001)。
  • RAD_HGP是1年PFS唯一独立预测因素。

临床应用与阅片要点

  • 阅片时可关注CRLM的HGP分型,影像组学模型辅助区分D型与R型,D型提示贝伐珠单抗化疗后PFS更长。
  • 对多病灶患者需综合评估各病灶HGP,混合型预后类似R型。

局限性

  • 回顾性研究设计。
  • 原文未报告其他明显局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the capability of a radiomics model, which was designed to identify histopathologic growth pattern (HGP) of colorectal liver metastases (CRLMs) based on contrast-enhanced multidetector computed tomography (ceMDCT), to predict early response and 1-year progression free survival (PFS) in patients treated with bevacizumab-containing chemotherapy.

METHODS: Patients with unresectable CRLMs who were treated with bevacizumab-containing chemotherapy were included in this multicenter retrospective study. For each target lesion, the radiomics-diagnosed HGP (RAD_HGP) of desmoplastic (D) pattern or replacement (R) pattern was determined. Logistic regression and receiver operating characteristic (ROC) curves were used to assess lesion- and patient-based responses according to morphologic response criteria. One-year PFS was calculated using Kaplan-Meier curves. Hazard ratios for 1-year PFS were obtained through Cox proportional hazard regression analysis.

RESULTS: Among 119 study patients, 206 D pattern and 140 R pattern lesions were identified. In patients with multiple lesions, 52 had D pattern, 31 had R pattern, and 36 had mixed (D + R) pattern. The area under the curve value for RAD_HGP in predicting early response was 0.707 for lesion-based analysis and 0.720 for patient-based analysis. Patients with D pattern had a significantly longer PFS than patients with R pattern or mixed pattern (P < 0.001). RAD_HGP was the only independent predictor of 1-year PFS.

CONCLUSIONS: HGP diagnosed using a radiomics model could be used as an effective predictor of PFS for patients with CRLMs treated with bevacizumab-containing chemotherapy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wei S, Han Y, Zeng H, et al. Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy. Eur J Radiol. 2021. PMID: 34343846. doi:10.1016/j.ejrad.2021.109863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。